The U.S. Supreme Court on Monday rejected a challenge to so-called pay-to-delay settlements between brand-name and generic drug companies.
The decision comes as President Obama, in his proposed budget, seeks a ban on such settlements, often called reverse payments. The administration said the ban would save $8.8 billion over the next 10 years.
No comments:
Post a Comment